Novartis muscle wasting drug gets 'breakthrough' status
ZURICH (Reuters) - Novartis said on Tuesday U.S. regulators have granted breakthrough therapy status for its investigational compound bimagrumab for the potential treatment of patients with sporadic inclusion body myositis (sIBM).
The U.S. Food and Drug Administration (FDA) created the "breakthrough therapy" designation earlier this year for medicines deemed likely to demonstrate "substantial improvement" over existing drugs.
sIBM is a rare yet potentially life-threatening muscle-wasting condition. Patients suffering from the disease can gradually lose the ability to walk. There are currently no approved treatments, according to Novartis.
Bimagrumab was developed by Novartis in collaboration with Morphosys. The drug works by stimulating muscle growth by blocking from inhibitory molecules.
(This corrects day of the week to Tuesday from Thursday)
(Reporting by Caroline Copley)
- Islamic State threat 'beyond anything we've seen': Pentagon
- National Guard start pullout as protests in Ferguson turn calmer |
- British Muslims blame jihadi subculture after beheading video |
- U.S. aid workers who survived Ebola leave Atlanta hospital |
- Class action against Facebook attracts 60,000 users